Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Champions OncologyCSBR -3.31%64 Earnings per Share (Diluted) is $-0.08 as of Apr. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.82 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,161 Biotechnology companies, Champions Oncology ranks better than 77.26% on this metric.
Champions Oncology's EPS (Basic) for the
three
months ended in Apr. 2026 was $-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.08.
During the past 13 years, Champions Oncology's highest 3-Year average EPS without NRI Growth Rate was 105.30% per year. The lowest was -188.40% per year. And the median was 13.60% per year.
Champions Oncology (NAS:CSBR) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Champions Oncology Earnings per Share (Diluted) Related Terms
Champions Oncology Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Earnings per Share (Diluted) Chart
CSBR vs RLYB, NRXS, VRCA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Champions Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's PE Ratio distribution charts can be found below:
* The bar in red indicates where Champions Oncology's PE Ratio falls into.
Champions Oncology Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Champions Oncology's Earnings Per Share (Diluted) for the fiscal year that ended in Apr. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.08 mean?
Champions Oncology (CSBR) has a Earnings per Share (Diluted) of $-0.08 as of Apr. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #264 out of 1161 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Champions Oncology's Earnings per Share (Diluted) too high?
Champions Oncology's current Earnings per Share (Diluted) is $-0.08. Based on the distribution chart, Champions Oncology ranks #264 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Earnings per Share (Diluted) compare to RLYB and NRXS?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #264 out of 1161 companies for Earnings per Share (Diluted). This places Champions Oncology in the top 23% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Earnings per Share (Diluted) is $-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.82, compared to a current price of $4.96 — trading 27.3% below its estimated fair value. The current Earnings per Share (Diluted) is $-0.08. Champions Oncology's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Earnings per Share (Diluted) is $-0.08 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $4.96 is trading 27.3% below its estimated GF Value™ of $6.82.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
Earnings per Share (Diluted): $-0.08
GF Value™: $6.82 vs. price of $4.96 (27.3% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
